We are currently developing the following cells that will be available for research use: midbrain dopaminergic neurons, forebrain parvalbumin-expressing interneurons, oligodendrocytes, hindbrain neurons, as well as functionally mature human pancreatic islet cells (beta cells).

In our R&D pipeline are cells of the three germ layers, all to be investigated as cell therapies for diabetes, cancer, bone marrow failures, Huntington’s disease, and more.

Using our unique technology platform, we are designing a triple-combination antiviral drug therapy that specifically targets SARS-CoV-2, the virus responsible for COVID-19.

Our HD-DoE^™ approach is a powerful technology platform that can extract conditions for making all types of specialized human cells, including brain neurons, insulin producing beta cells, endothelial cells, pigment epithelial cells, collecting duct cells, and bronchiolar cells, to name a few.

Founded in 2015, we pioneered HD-DoE^™, merging developmental biology and cell therapeutics with cutting-edge hardware plus computerized experimental design and analysis.

At Trailhead Biosystems, we have recruited some of the best and brightest in our industry to join us in our mission: Meet our visionary Leadership Team and Board of Directors.

Are you interested in joining the Trailhead team? Read on to gain insight into our generous benefits, company culture, desirable locations—and the mission that drives us.

Motivated, passionate, adaptable, skilled, and dedicated to making positive change—sound like you? Trailhead Biosystems is actively hiring! Check out our open positions.